Near-infrared fluorescent contrast bioimaging agents for sentinel lymph node imaging
The development of Indocyanine Blue as a near-infrared fluorescent contrast agent addresses solubility and target specificity issues in SLN mapping, enhancing imaging efficacy and safety by improving solubility and SBR.
Patent Information
- Application Number
- JP2024536174
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-16
- Filing Date
- 2022-12-14
- Publication Date
- 2025-01-09
AI Technical Summary
Current near-infrared (NIR) fluorophores for sentinel lymph node (SLN) mapping suffer from low solubility, rapid clearance, and lack of target specificity, leading to poor signal-to-background ratios (SBR) and non-specific background uptake, limiting their effectiveness in imaging applications.
Development of a near-infrared fluorescent contrast agent, Indocyanine Blue (ICB), which is more hydrophilic due to sulfobutyl and shorter alkynylene chains, allowing it to accumulate in sentinel lymph nodes effectively and be cleared efficiently, with optional conjugation for additional imaging modalities like SPECT, PET, or MRI.
ICB achieves improved solubility, targeted accumulation, and enhanced SBR, facilitating clearer SLN mapping with reduced side effects and increased safety, enabling effective imaging and therapeutic applications.
Smart Images

Figure 2025500272000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 290,286, filed December 16, 2021, the entire contents of each of which are incorporated herein by reference in their entirety. [Background technology]
[0002] Near infrared (NIR) fluorescence is of potential importance in the medical field, especially in in vitro diagnosis, in vivo diagnosis and image-guided surgery. However, the availability of suitable fluorophores as imaging agents has been a major obstacle. To be viable, an ideal NIR fluorophore should have good optical properties and excellent physicochemical properties in terms of solubility, biodistribution, targeting and clearance. Most current fluorophores intended for use as imaging agents fail in relation to their physicochemical properties. For example, known fluorophores either fail to accumulate adequately in the target to be imaged (i.e. low signal), resulting in a low signal-to-background ratio (SBR), or exhibit significant non-specific background uptake in normal tissues (i.e. high background), resulting in a low SBR as well.
[0003] In particular, mapping of sentinel lymph nodes poses additional challenges. Sentinel lymph node biopsy (SLB or SLN biopsy) allows selective and minimally invasive access to determine the status of regional lymph nodes with malignancies. The first draining lymph node, the "sentinel", represents a pre-existing or non-pre-existing tumor in the entire nodal basin. The method has been validated using radionuclides and / or blue dye for breast cancer, malignant melanoma, and also gastrointestinal tumors, achieving satisfactory detection rates and sensitivity. Although a reduction in mortality has been observed with SLB compared to complete lymphadenectomy, the method has disadvantages related to availability, application, disposal of radionuclides, and risk of anaphylaxis to blue dye (up to 1%).
[0004] Indocyanine green (ICG) is a fluorescent dye that is administered intravenously and cleared from the body with a half-life of approximately 3-4 minutes depending on liver capacity. ICG is metabolized in the liver and excreted only via the liver and bile duct. It can be classified as low toxic because it is not absorbed by the intestinal mucosa. Nevertheless, ICG is known to degrade into toxic waste materials under the influence of ultraviolet light, creating several unknown substances. Side effects such as anaphylactic shock, low blood pressure, rapid heartbeat, dyspnea, and urticaria occur rarely, but the risk of severe side effects is elevated in patients with chronic renal dysfunction.
[0005] Currently, ICG is used for SLN mapping, but is considered effective due to its hydrophobic nature. Nevertheless, ICG has limited biological applications due to its low stability in water in vitro, concentration-dependent aggregation, rapid clearance from the body, and lack of target specificity. Other compounds, such as those disclosed in WO2015066290A1, have been shown to be useful for SLN mapping. Nevertheless, the compounds described therein for SLN mapping are also hydrophobic in nature and difficult to formulate for biological applications.
[0006] Thus, there is currently a need for new and improved NIR fluorescent imaging agents for SLN mapping, particularly NIR fluorescent imaging agents that are readily soluble, rapidly equilibrate between the intravascular and extravascular spaces, target various cells, tissues or organs with high sensitivity and specificity, and are efficiently cleared from the body when not targeted. The imaging agents of the present invention address these and other needs. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] International Publication No. 2015066290A1 [Patent Document 2] European Patent No. 2152810A1
Patent Document 3
Patent document 4
Patent document 5
Patent document 6
Patent document 7
Patent document 8
Non-licensed literature
[0008] [Non-licensed document 1] Michael B. Smith, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 7th Edition, Wiley (2013) [Non-licensed document 2] Henary, M., Bioorg. & Med. Chem. Let. 22, 242~1246 pages (2012) [Non-licensed document 3] Henary, M.ら, J. Heterocycl. Chem. 46: Pages 84~87 (2009)
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non - Patent Document 8
Non - Patent Document 9
Non - Patent Document 10
Non - Patent Document 11
Non - Patent Document 12
Non - Patent Document 13
Non - Patent Document 14
Non - Patent Document 15
Non - Patent Document 16
Non - Patent Document 17
Non - Patent Document 18
[0009] The present invention is directed, at least in part, to near-infrared fluorescent imaging agents and methods of using same. [Means for solving the problem]
[0010] In one embodiment, the near infrared fluorescent imaging agent is 4-[(2Z)-2-[(2E,4E)-5-[3,3-dimethyl-1-(4-sulfobutyl)indol-1-ium-2-yl]penta-2,4-dienylidene]-3,3-dimethylindol-1-yl]butane-1 sulfonic acid:
[0011] [ka]
[0012] .
[0013] This compound is also known as MHI85, CUR-438, CID:87460681, SCHEMBL2969196 or indocyanine blue (ICB).
[0014] In certain embodiments, the imaging agent has an absorbance peak between about 600 nm and 900 nm.
[0015] In certain embodiments, tissues or cells are imaged ex vivo, for example for in vitro diagnostic applications.
[0016] In another aspect, the present invention provides a method of imaging sentinel lymph nodes (i.e., sentinel lymph node tissue, cells, blood vessels and / or lumen) comprising: (a) contacting one or more sentinel lymph nodes with an ICB; (b) irradiating the cells with a wavelength absorbed by the ICB; and (c) detecting a signal from the ICB, thereby imaging the sentinel lymph node.
[0017] In certain embodiments, the compounds of the invention accumulate in a tissue or organ but not extracellularly, for example, a compound injected subdermally can enter the lymphatics and flow to the sentinel lymph node, where it can become trapped in the extracellular space rather than, or in addition to, pooling intracellularly in the sentinel lymph node.
[0018] In certain embodiments, the compounds of the present invention may be modified to include a polyethylene glycol group. Such PEGylated compounds may be branched or linear. In certain embodiments, linear PEGylated compounds are about 20 kDa to about 60 kDa.
[0019] In certain embodiments, ICB may be covalently or non-covalently conjugated to other molecules to either improve targeting of the NIR fluorophore or to colocalize other functional molecules.
[0020] In some embodiments, ICB can be conjugated to a metal chelator for use in single photon emission computed tomography (SPECT), or positron emission tomography (PET), or magnetic resonance imaging (MRI). In certain embodiments, the metal chelator is DOTA, DTPA, hydrazinonicotinic acid (HYNIC), or deferoxamine, or a derivative thereof. In certain embodiments, the metal atom is selected from the group including, but not limited to, Zr-89, Ga-68, and Rb-82, and the signal is detected by positron emission tomography; the metal atom is selected from the group including, but not limited to, Tc-99m, Lu-177, and In-111, and the signal is detected by single photon emission computed tomography; or the metal atom is a lanthanide selected from the group including, but not limited to, Gd, Eu, Y, Dy, and Yb, and the signal is detected by magnetic resonance imaging.
[0021] In some embodiments, ICB may be conjugated to a therapeutic agent, such as a radioisotope, cytotoxin, or immunomodulator, such that the targeting ability of the compound concentrates the therapeutic agent in a cell, tissue, organ, or cavity of a subject.
[0022] FIG. 1 shows imaging of sentinel lymph nodes at 700 nm and 800 nm using indocyanine blue, indocyanine green, and MHI86 (images without illumination, NIR illuminated image, overlay of both). [Brief description of the drawings]
[0023] [Figure 1] Figure 1 shows imaging of SLN identification at 700 nm using MHI86 (image without illumination, NIR illuminated image, overlay of both). Figure 1 shows imaging of SLN identification at 700 nm using ICB and ICG (image illuminated at 700 nm, NIR illuminated image, overlay of both). [Diagram 2]FIG. 1 shows imaging of SLN identification at 700 nm using SLN700 and ICG (700 nm illuminated image, NIR illuminated image, overlay of both). [Diagram 3] FIG. 1 shows imaging of SLN identification at 700 nm using SLN700 and ICB (700 nm illuminated image, NIR illuminated image, overlay of both). [Figure 4] FIG. 1 shows imaging of SLN identification after tail circumference intradermal injection using SLN700 (700 nm), ICB (called CUR-438, 700 nm), and ICG (800 nm). [Figure 5A] FIG. 1 shows the biodistribution of SLN700 4 hours after intravenous injection. [Figure 5B] FIG. 1 shows the biodistribution of ICB (referred to as CUR-438) 4 hours after intravenous injection. [Figure 5C] FIG. 1 shows the biodistribution of ICG 4 hours after intravenous injection. [Figure 6] FIG. 13. Imaging of SLN identification at 700 nm using MHI86 (image without illumination, image with NIR illumination, overlay of both). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Abbreviations used: LN: Lymph node SLN: Sentinel lymph node SBR: signal to background ratio
[0025] Compounds that absorb and / or emit in the near infrared (NIR) have been found to have desirable properties with respect to in vivo biodistribution and clearance, uptake and retention by cells, tissues and / or organs of interest, and imaging thereof. Such agents are compatible with Channel 1 (≈660 nm excitation; ≈700 nm emission) or Channel 2 (≈760 nm excitation; ≈800 nm emission) of the FLARE™ Imaging System, which allows for simultaneous acquisition of color video and NIR fluorescence, thus providing surgeons and the like with real-time image guidance of the target location.
[0026] definition The following definitions will be useful in understanding the present invention.
[0027] Throughout the specification, including the claims, the following terms shall have the meanings indicated. Words and phrases used herein should be understood and interpreted to have a meaning consistent with the understanding of those words and phrases by those skilled in the relevant art. No special definition of a term or phrase, i.e., any definition that is different from the ordinary and customary meaning as understood by those skilled in the art, is intended to be implied by the consistent usage of the term or phrase herein. If a term or phrase is intended to have a special meaning, i.e., a meaning other than the broadest meaning as understood by those skilled in the art, such special and specific definition will be expressly set forth herein in the definition format that provides a special and specific definition for the term or phrase.
[0028] For example, the following discussion contains a non-exhaustive list of definitions of some specific terms used in this disclosure (other terms may be defined or clarified in a definitional manner elsewhere herein). These definitions are intended to clarify the meaning of the terms used herein. It is believed that the terms are used in a manner consistent with their ordinary meaning, but the definitions are nevertheless provided here for clarity.
[0029] A / an: As used herein, the articles "a" and "an" mean one or more when applied to any feature within the embodiments and implementations of the present disclosure described in the specification and claims. The use of "a" and "an" does not limit the meaning to a single feature unless such a limitation is specifically stated. The term "a" or "an" entity refers to one or more of that entity. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.
[0030] About: As used herein, "about" refers to a degree of deviation based on experimental error typical for the particular property identified. The tolerance provided for the term "about" will depend on the particular context and the particular property and can be easily discerned by one skilled in the art. The term "about" is not intended to either expand or limit the degree of equivalence to which a particular value may otherwise be given. Moreover, unless otherwise indicated, the term "about" expressly includes "exactly" consistent with the following discussion of ranges and numerical data. All numerical values within the detailed description and claims herein are modified by the indicated value "about" or "approximately" to account for experimental error and variations that would be expected by one of ordinary skill in the art.
[0031] And / or: The term "and / or" placed between a first entity and a second entity means one of: (1) the first entity, (2) the second entity, and (3) the first entity and the second entity. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so combined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related to the elements specifically identified or not. Thus, as a non-limiting example, a reference to "A and / or B," when used with open-ended language such as "comprising," may refer in one embodiment to A only (optionally including elements other than B); in another embodiment to B only (optionally including elements other than A); in yet another embodiment to both A and B (optionally including other elements). Herein, in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when distinguishing items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., including at least one of a number or list of elements, but including more than one, optionally including additional items not listed. Only terms clearly indicating the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, as used herein, the term "or" shall only be construed as indicating exclusive alternatives (i.e., "one or the other, but not both") when preceded by exclusivity terms such as "either," "one of," "only one of," or "exactly one of."
[0032] Comprising: In the claims and specification, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, are to be understood to be open-ended, i.e., to mean including, but not limited to, the following. Only the transitional phrases "consisting of" and "consisting essentially of," respectively, are intended to be closed or semi-closed transitional phrases, as set forth in the U.S. Patent Office Guidelines for Patent Examination, Section 2111.03. Any device or method or system described herein may be comprised of, consist of, or consist essentially of any one or more of the described elements.
[0033] In particular, as used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. "Consisting essentially of," when used to define compositions and methods, is intended to mean excluding any other elements of essential importance to the combination. Thus, a composition consisting essentially of the elements defined herein does not exclude trace contaminants from the isolation and purification methods, as well as pharmacy acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of" is intended to mean excluding other ingredients beyond trace elements and substantial method steps for administering the compositions of the invention. Embodiments defined by each of these transition terms are within the scope of the invention.
[0034] Ranges: Concentrations, dimensions, amounts, and other numerical data may be presented herein in a range format. It should be understood that such range formats are used merely for convenience and brevity, and should be interpreted flexibly to include not only the numerical values explicitly recited as the boundaries of the range, but also all of the individual numerical values or subranges subsumed within the range, as if each numerical value and subrange were specifically recited. For example, the range from about 1 to about 200 should be interpreted not only to include the explicitly recited boundaries of 1 and about 200, but also to include individual sizes of 2, 3, 4, etc., and subranges such as 10-50, 20-100, etc. Similarly, when numerical ranges are provided, it should be understood that such ranges should be interpreted as providing literal support for the limitations of the claims reciting only the lower values of the ranges and for the limitations of the claims reciting only the upper values of the ranges. For example, a disclosed numerical range of 10-100 provides literal support for claims reciting "greater than 10" (without an upper limit) and claims reciting "less than 100" (without a lower limit). In the figures, like numbers refer to like or similar structures and / or features; each illustrated structure and / or feature may not be described in detail herein with reference to the figures. Similarly, each structure and / or feature may not be explicitly labeled in the figures; any structure and / or feature discussed herein with reference to the figures may be utilized with any other structure and / or feature without departing from the scope of the present disclosure.
[0035] For the sake of brevity, only certain ranges are explicitly disclosed herein. However, a range from any lower limit may be combined with any upper limit to enumerate a range not specifically recited, and a range from any lower limit may be combined with any other lower limit to enumerate a range not specifically recited, and in the same manner, a range from any upper limit may be combined with any other upper limit to enumerate a range not specifically recited. In addition, even if not specifically recited, a range includes every point or individual value between its endpoints. Thus, every point or individual value may act as its own lower or upper limit in combination with any other point or individual value or any other lower or upper limit to enumerate a range not specifically recited.
[0036] The recitation of a listing of chemical groups in any definition of a variable herein includes the definition of that variable as any single group or combination of listed groups. The recitation of an embodiment or aspect with respect to a variable herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0037] As used herein, the term "subject" or "patient" includes mammals and non-mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, monkeys, cows, horses, sheep, goats, pigs; rabbits, dogs, cats, rats, mice, guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, parasites, microorganisms, etc.
[0038] As used herein, the terms "administration" or "administering" a subject compound refer to providing a compound of the invention and / or a prodrug thereof to a subject in need of diagnosis or treatment.
[0039] As used herein, the term "carrier" refers to a chemical compound or agent that facilitates the incorporation of a compound described herein into cells or tissues.
[0040] As used herein, the term "acceptable" with respect to a formulation, composition or containing substance means having no lasting deleterious effects on the overall health of the subject being treated.
[0041] As used herein, the term "diluent" refers to a chemical compound used to dilute the compounds described herein prior to delivery. Diluents can also be used to stabilize the compounds described herein.
[0042] Other definitions are provided in the context throughout this disclosure.
[0043] Compounds and Compositions Certain compounds have been found to be useful as near-infrared absorbing and / or fluorescent biological imaging agents.
[0044] In one embodiment, the near infrared fluorescent imaging agent is 4-[(2Z)-2-[(2E,4E)-5-[3,3-dimethyl-1-(4-sulfobutyl)indol-1-ium-2-yl]penta-2,4-dienylidene]-3,3-dimethylindol-1-yl]butane-1 sulfonic acid:
[0045] [ka]
[0046] or a salt, solvate, hydrate, polymorph, prodrug, or stereoisomer thereof.
[0047] This compound is also known as MHI85, CUR-438, CID:87460681, SCHEMBL2969196 or indocyanine blue (ICB).
[0048] In certain embodiments, ICB can absorb light at different wavelengths in the near infrared. In particular, in some embodiments, the compounds of the present invention absorb light in the range of 660-720 nm. In other embodiments, the compounds of the present invention absorb light in the range of 760-820 nm.
[0049] Due to its increased hydrophilicity, ICB is more soluble in water and other carriers compared to ICG. The increased hydrophilicity of ICB is due to the shorter alkynylene chain connecting the benzoindole groups. In addition, the inclusion of a sulfobutyl group also greatly increases the hydrophilicity of ICB. Despite its relative lack of hydrophobicity, ICB was unexpectedly and surprisingly found to be readily retained by sentinel lymph nodes in amounts effective for SLN mapping.
[0050] In certain embodiments, the ICB has a single photon or positron radiative decay mode in addition to detection by optical properties (i.e., absorption and / or fluorescence), and contains a radioisotope suitable for detection by single photon emission computed tomography (SPECT) or positron emission tomography (PET). Examples of suitable radioisotopes include C-11 and F-18. Such isotopes can be incorporated into the compounds of the invention, for example, by using suitable isotopically enriched reagents during compound synthesis. Further useful radiotracers, such as Ga-68, Zr-89, or Rb-82 (PET), or Tc-99m (SPECT), can be bound to the compounds via radiometal chelators, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), diethylenetriaminepentaacetic acid (DTPA), hydrazinonicotinic acid (HYNIC), or deferoxamine, respectively (or derivatives thereof). The chelator moiety can be covalently attached to the oxazine compound, for example, via a linking atom or group, for example, by acylation of a hydroxyl group of the compound of formula IV with a carboxylate group of a chelator such as DOTA. By incorporation of a suitable PET or SPECT detectable isotope, the compounds according to the invention can be detected using SPECT or PET imaging, for example, using conventional SPECT or PET imaging systems (e.g., even when administered at low doses), but can also be optically detectable (e.g., by fluorescence imaging), for example, when administered at higher doses. Dual mode optical and SPECT or PET imaging can also be enabled using such compounds. Similarly, imaging by magnetic resonance imaging (MRI), including dual mode optical / MRI imaging, can be performed using lanthanides (Yb 3+ , Dy 3+ or Gd 3+ etc.), for example, by chelating the lanthanide ion using a suitable chelating moiety.
[0051] ICBs can be prepared using a variety of methods, some of which are known to those skilled in the art. For example, the compounds can be prepared using conventional methods of organic synthetic chemistry (see, for example, Michael B. Smith, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, Wiley (2013)).
[0052] For example, ICB can be synthesized using the synthesis set forth in Scheme 1 shown below. General references for the synthesis described in Scheme 1 are: Henary, M. et al., Bioorg. & Med. Chem. Let. 22, 242-1246 (2012); Henary, M. et al., J. Heterocycl. Chem. 46: 84-87 (2009); Henary, M. et al., Dyes and Pigments. 99, 1107-1116 (2013); Henary, M. et al., Heterocycl. Commun. 19 (1), 1-11 (2013); Mojzych, M. et al., Topics in Heterocyclic, Springer-Verlag Berlin Heidelberg. 14, 1-9 (2008); Strekowski, L. et al., J. Org. Chem. 57, 4578-80(1992); Halder, S. et al., Eur. J. Med. Chem. 54, 647-59(2012); Sakiko, A. et al., Chem.-A Eur. J., 15, 9191-9200(2009); Chang, YT. et al., Chem. Commun. 47, 3514-3516(2011); Myochin, TJ, Am. Chem. Soc.134,13730-13737(2012); Briza, T. et al., Chem. Comm. 16, 1901-1903(2008); Chang, YT. et al., Chem. Commum. 46, 7406-7408 (2010); Zaheer, A., et al., Molecular Imag. 1 (4), 1536-0121 (2002); Misra, P. et al., J Nucl Med. 2007 Aug;48(8):1379-89; and Humblet, V. et al., J Med Chem. 2009 Jan 22;52(2):544-50.
[0053] [ka]
[0054] ICB can also be synthesized using a three-step synthesis as described in Scheme 2 below:
[0055] [ka]
[0056] Furthermore, ICB may also be synthesized using the methods disclosed in WO2015066290A1, EP2152810A1, U.S. Patent No. 20080254546A1, U.S. Patent No. 20100216182A1, U.S. Patent No. 7776999B2, U.S. Patent No. 8354499B2, WO2008127768A1, each of which is incorporated by reference.
[0057] As would be readily understood by one of skill in the art, ICB, including its salts, solvates, and hydrates, may be synthesized using the methods outlined above or using modification of starting materials and other reagents.
[0058] composition In another aspect, the present invention provides a pharmaceutical composition of ICB, or a pharma- ceutically acceptable salt, solvate or hydrate thereof.
[0059] For the therapeutic uses provided herein, ICB, including its pharma- ceutically acceptable salts, solvates, N-oxides, prodrugs, or isomers, is administered in a therapeutically effective amount alone or as part of a pharmaceutical composition. Thus, provided herein are pharmaceutical compositions that include at least ICB, its pharma- ceutically acceptable salts and / or solvates, and one or more pharma- ceutically acceptable carriers, diluents, adjuvants, or excipients. Methods of administration of ICB or compositions of ICB include, but are not limited to, intravenous, inhalation, oral, rectal, parenteral, intravitreal, intratumoral, subcutaneous, intramuscular, intranasal, dermal, topical, ocular, buccal, tracheal, bronchial, sublingual, or ocular. The compounds provided herein are administered in known pharmaceutical formulations, including tablets, capsules, or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and lotions, gels, ointments, or creams for topical administration.
[0060] In certain embodiments, ICB may be administered directly without any additional formulation, nevertheless, due to its increased solubility, ICB may be easily dissolved in water, saline, 5% dextrose in water (D5W), or other carriers for administration.
[0061] The amount administered will vary depending on, among other things, the tissue or organ being imaged, the age and relative health of the subject, the potency of the compound administered, the mode of administration, etc. In some embodiments, ICB is administered as a 0.1 mL to 5 mL injection of a 1.0 to 5.0 mM solution. In certain embodiments, ICB is administered as a 1.0 mL to 2.5 mL injection of a 1.0 to 3.0 mM solution. In certain embodiments, ICB is administered as a 1.0 mL injection of a 2.5 mM solution, which corresponds to 2.5 μmoles or 1.57 mg of compound.
[0062] Pharmaceutically acceptable salt forms include pharma- ceutically acceptable acid / anionic or basic / cationic salts. Pharmaceutically acceptable acid / anionic salts include acetate, benzenesulfonate, benzoate, bicarbonate, acid tartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycolyl arsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthalene ... Pharmaceutically acceptable basic / cationic salts include sodium, potassium, calcium, magnesium, diethanolamine, N-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine, and triethanolamine salts.
[0063] Pharmaceutically acceptable acid salts are formed by reaction of the free base form of ICB with a suitable inorganic or organic acid, including, but not limited to, hydrobromic acid, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, maleic acid, formic acid, acetic acid, propionic acid, fumaric acid, citric acid, tartaric acid, lactic acid, benzoic acid, salicylic acid, glutamic acid, aspartic acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, naphthalenesulfonic acids such as 2-naphthalenesulfonic acid, or hexanoic acid. Pharmaceutically acceptable acid addition salts of the compounds of formula I can include or be, for example, hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate, such as 2-naphthalenesulfonate, or hexanoate.
[0064] The free acid or free base forms of ICB can be prepared from the corresponding base addition salt or acid addition salt forms, respectively. For example, an acid addition salt form of ICB can be converted to the corresponding free base form by treatment with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, etc.). A base addition salt form of ICB can be converted to the corresponding free acid by treatment with a suitable acid (e.g., hydrochloric acid, etc.).
[0065] Prodrug derivatives of ICB can be prepared by methods known to those of skill in the art (see, for example, Saulnier et al., Bioorg. Med. Chem. Letters, 1994, 4, 1985, for details; the entire teachings of which are incorporated herein by reference).
[0066] Protected derivatives of ICB can be prepared by means known to those skilled in the art. A detailed description of techniques applicable to the creation and removal of protecting groups can be found in TW Greene, "Protecting Groups in Organic Chemistry", 3rd Edition, John Wiley and Sons, Inc., 1999, the entire teachings of which are incorporated herein by reference.
[0067] Pharmaceutically acceptable carriers, diluents, adjuvants or excipients suitable for use in the pharmaceutical compositions of the present invention include, for example, tablets (coated tablets), capsules (gelatin), liquids (aqueous or aqueous ethanolic solutions), syrups containing the active substances, emulsions or inhalable powders (mixtures of various sugars, such as lactose or glucose, salts and these excipients with one another) and aerosols (inhalable solutions with or without a propellant).
[0068] Excipients that may be used include carriers such as, for example, water, pharma- ceutically acceptable organic solvents such as paraffin (e.g., petroleum fractions), vegetable oils (e.g., peanut oil or sesame oil), monofunctional or polyfunctional alcohols (e.g., ethanol or glycerol), natural mineral powders (e.g., kaolin, clay, talc, chalk), synthetic mineral powders (e.g., highly dispersed silicic acid and silicates), sugars (e.g., sucrose, lactose and glucose), emulsifiers (e.g., lignin, spent sulfite liquor, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g., magnesium stearate, talc, stearic acid and sodium lauryl sulfate).
[0069] Exemplary methods for preparing the compounds of the invention are described herein, including the Examples.
[0070] method The invention features various methods of using the near-infrared fluorescent biological imaging agents described herein.
[0071] In one aspect, the present invention provides a method of imaging a biological tissue or cell, the method comprising: (a) contacting a biological tissue or cell with indocyanine blue (ICB) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof; (b) irradiating the biological tissue or cells with a wavelength absorbed by ICB; (c) detecting a signal from the ICB, thereby imaging the biological cell.
[0072] The signal may be in the form of absorption, as occurs during photoacoustic imaging. Alternatively, the imaging agent may have an appropriate SBR to allow for fluorescence detection. SBR is a measure of the intensity of a fluorescent signal (peak signal) obtained from a target relative to a measure of the intensity of a fluorescent signal obtained near the target (background signal), the target being a tissue, cell, or space targeted by the imaging agent. SBR measurements can be easily obtained by routine measurement procedures. For fluorescent imaging systems and other optical-based systems, a digital image recording the optical signal of the target facilitates SBR measurements. Higher SBR values are more desirable, resulting in higher resolution of the imaged tissue. In some embodiments, the imaging agent achieves an SBR of at least about 1.1 (i.e., the peak signal is at least 10% higher than the background). In further embodiments, the imaging agent achieves an SBR of at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, or at least about 2.0. In still further embodiments, the imaging agent achieves an SBR of from about 1.1 to about 50, from about 1.5 to about 30, from about 2.0 to about 20, from about 2.0 to about 5.0, or from about 5.0 to about 10.
[0073] In certain embodiments, the imaging agent is administered directly to a subject or biological system to image targeted cells.
[0074] In other embodiments, the reactive derivatives of the imaging agents are used to label chemical and biological molecules for further study. Particular molecules that can be labeled using the reactive derivatives of the imaging agents of the present invention include small molecules, including pharmaceuticals, nutraceuticals, therapeutic and diagnostic compounds, proteins, peptides, peptidomimetics, antibodies, vaccines, and other chemical and biological molecules that are interesting for study by NIR imaging. In such embodiments, the imaging agents of the present invention are reacted with chemical or biological molecules to produce labeled drug molecules that can then be administered to a subject or biological system for imaging as described herein.
[0075] The steps of illuminating the tissue or cell with a wavelength absorbed by the imaging agent and detecting light signals from the illuminated tissue or cell, thereby imaging the tissue or cell, may be performed using an imaging system such as the FLARE™ image-guided surgery system, which is a continuous wave (CW) intraoperative imaging system capable of simultaneous real-time acquisition and display of two channels of color video (i.e., surgical anatomy) and invisible NIR fluorescent light (700 nm and 800 nm) (see, e.g., Gioux et al., Mol. Imaging. 9(5): 237-255 (2010) and U.S. Pat. No. 8,473,035 to Frangioni for a description of a suitable system). When using FLARE™ and other NIR fluorescent imaging systems, contrast agent emission wavelengths in the range of 800-850 nm [channel 2 of FLARE™] are preferred whenever possible due to lower autofluorescence and lower attenuation from both absorption and scattering when compared to emissions near 700 nm. Nonetheless, fluorophore emission in channel 1 (≈700 nm) of the FLARE™ imaging system still retains the benefits of NIR fluorescence imaging, including detection of nerves and other targets below the surface of blood and tissue.
[0076] In some embodiments, the imaging agent can be formulated into a pharma- ceutically acceptable preparation and administered intravenously to an organism for imaging. The dosed organism can be imaged, for example, using the FLARE™ system. The imaging system can irradiate the dosed organism with radiation that is absorbed by the imaging agent and detect optical signals, such as NIR fluorescence, emanating from portions of the targeted organism that contain the imaging agent. The detected signals can be recorded and analyzed by obtaining digital images or videos of the target organism, thereby facilitating diagnostic procedures and image-guided medical techniques.
[0077] The present invention also provides a method of performing image-guided surgery, which comprises imaging a cell, tissue or organ according to the methods described herein and then performing surgery such that the target is either removed or preserved, depending on the purpose of the surgical intervention. In certain preferred embodiments, the imaging agent is injected intravenously to ensure that all targets are labeled, and imaging is performed after sufficient time has elapsed for nerve biodistribution and clearance of surrounding background signal.
[0078] In certain embodiments, the target is a biological tissue or organ, hi certain embodiments, the target is an internal cavity, such as a sentinel lymph node.
[0079] It should also be noted that although the examples below are for in vivo imaging, they represent the most challenging situations since properties such as biodistribution and clearance are highly influenced by the organism, and those skilled in the art will recognize that these same imaging agents can be used for any type of in vitro assay, such as immunohistology, detection of targets in blood or body fluid samples, using the same principles of contact with the medium, washing of the unbound dose, and detection of signals resulting from absorption, fluorescence and / or radioactivity.
[0080] Sentinel lymph node: Sentinel lymph node mapping has revolutionized the treatment of breast cancer and melanoma. However, 20-25% of patients are found to have tumor cells in their sentinel lymph nodes and therefore require a complete lymphadenectomy, i.e., removal of all lymph nodes in the basin. Finding all lymph nodes in a body area can be extremely difficult.
[0081] Sentinel lymph node drugs are injected into and around a tumor and rapidly drain to the first lymph node that drains the tumor, called the sentinel lymph node (SLN).
[0082] Thus, in one aspect, the present invention provides a method of imaging a sentinel lymph node, the method comprising: (a) contacting the sentinel lymph node with indocyanine blue (ICB) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof; (b) irradiating the tissue with light of a wavelength absorbed by ICB; (c) detecting a signal from the ICB, thereby imaging the sentinel lymph node.
[0083] In certain embodiments, the illuminating wavelength for use in imaging the sentinel lymph node is between 660 and 700 nm.
[0084] In another specific embodiment, the illuminating wavelength for use in imaging the sentinel lymph node is between 760 and 800 nm.
[0085] In certain embodiments, ICB can be used for mapping sentinel lymph nodes. In yet other embodiments, the compounds of the present invention can be used for identifying breast cancer. In such embodiments, the sentinel lymph nodes of an organism are imaged to obtain a map of the sentinel lymph nodes. A sample of the sentinel lymph nodes is then removed by biopsy, and the removed nodes are examined to determine whether breast cancer cells are present. In such embodiments, the method of examining the removed nodes is not particularly limited and can be easily understood by those skilled in the art of diagnosing breast cancer.
[0086] Angiography: Mapping the vasculature in and around lymph nodes during surgery can often aid in resection procedures. Mapping the vasculature, called angiography, is used to visualize the body's blood vessels and the interiors or lumens of organs, with particular interest within arteries, veins, and cardiac chambers.
[0087] NIR fluorophores injected into the bloodstream can act as angiographic contrast agents because during the first 8 seconds after intravenous injection there is rapid arterial inflow (≈1 second), rapid capillary inflow (2-3 seconds), rapid venous inflow (≈1-2 seconds), and then clearance from the tissue for several minutes. Thus, the first 8 seconds provide a "map" of circulation within the tissue. NIR angiography is important for imaging skin perfusion during plastic and reconstructive surgery as well as intestinal anastomoses during gastrointestinal surgery. In general, NIR angiographic contrast agents are those that are rapidly cleared from the blood into either urine or bile.
[0088] Thus, in one aspect, the present invention provides a method of performing angiography in an organism, the method comprising: (a) administering to an organism an imaging composition, the imaging composition comprising an imaging agent, and the administering step comprising contacting a blood vessel, a lymph node and / or a coronary cavity of the organism with the imaging agent, the imaging agent comprising:
[0089] [ka]
[0090] or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the blood vessels, lymph nodes and / or coronary cavity with a wavelength absorbed by the imaging agent; (c) detecting a signal from the imaging agent and identifying blood vessels, lymph nodes and / or coronary cavities.
[0091] In another aspect, the present invention provides a method for imaging tissue perfusion, the method comprising: (a) contacting the blood with an imaging composition, the imaging composition comprising an imaging agent, and the imaging agent comprising:
[0092] [ka]
[0093] or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the blood vessel and surrounding tissue with a wavelength that is absorbed by the imaging agent; (c) detecting a signal from the compound, thereby imaging the distribution and clearance of the imaging agent in the tissue over time. EXAMPLES
[0094] The following examples are put forward so as to provide those of skill in the art with a complete disclosure and description of how to make and use the assay, screening, and treatment methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention.
[0095] Example 1 SYNTHETIC EXAMPLES - COMPOUNDS AND COMPOSITIONS Indocyanine blue is prepared according to the method described in Scheme 1.
[0096] A composition of indocyanine blue is prepared by dissolving indocyanine blue in water or D5W to a concentration of 2.5 mM.
[0097] Example 2 Optical properties / SLN mapping Optical property measurement Absorbance and fluorescence emission spectra were measured using a fiber optic HR2000 absorbance (200-1100 nm) and USB2000FL fluorescence (350-1000 nm) spectrometer (Ocean Optics, Dunedin, FL). Excitation was provided by a 532 nm green laser pointer (Opcom, Xiamen, China) set at 5 mW, a 655 nm red laser pointer (Opcom, Xiamen, China) set at 5 mW, or a 770 nm NIR laser diode source (Electro Optical Components, Santa Rosa, CA) set at 10 mW, coupled via a 300 μm central diameter, NA 0.22 fiber (Fiberguide Industries, Stirling, NJ). In silico calculations of the partition coefficient at pH 7.4 (logD at pH 7.4) as well as the surface molecular charge and hydrophobicity were calculated by using the major microspecies using MarvinSketch 5.2.1 (ChemAxon, Budapest, Hungary).
[0098] NIR Fluorescence Imaging System Near-infrared fluorescence imaging can be achieved using several commercially available imaging systems. For example, the dual NIR channel FLARE imaging system has been detailed. The system provides 40,000 lx of white light (400-650 nm), 4 mW / cm 2 at 660 nm NIR channel 1 excitation and 10 mW / cm 2A 760 nm NIR channel 2 excitation was provided for simultaneous illumination at 400 x 1000 nm. Color and two independent NIR fluorescence emission images (≈700 nm for channel 1 and ≈800 nm for channel 2) were acquired simultaneously at a rate of 15 Hz or less for a field of view diameter of 15 cm using custom-written software. The NIR fluorescence from channel 1 was pseudocolored red and the NIR fluorescence from channel 2 was pseudocolored yellow-green before being combined with the color video image. The imaging system was positioned 18 inches away from the surgical field.
[0099] NIR fluorescence imaging in animal models and during surgery Animals were housed in an AAALAC-accredited facility. Animal studies were performed under the supervision of the Institutional Animal Care and Use Committee (IACUC) of Beth Israel Deaconess Medical Center and in accordance with approved institutional protocols (#101-2011 for rodents and #046-2010 for swine).
[0100] Initial in vivo screening was performed in mice, rats and pigs. In the animal studies described below, 25 g CD-1 mice of either sex (Charles River Laboratories, Wilmington, MA) and 250 g Sprague-Dawley (SD) rats of either sex (Taconic Farms, Germantown, NY) were used after intraperitoneal anesthesia with 100 mg / kg ketamine and 10 mg / kg xylazine (Webster Veterinary, Fort Devens, MA). Yorkshire pigs of either sex (EM Parsons and Sons, Hadley, MA) weighing an average of 35 kg were induced with 4.4 mg / kg intramuscular Telazol™ (Fort Dodge Labs, Fort Dodge, IA), intubated and maintained with 2% isoflurane (Baxter Healthcare, Deerfield, IL). After anesthesia, a 16 G central venous catheter was inserted into the external jugular vein and saline was administered as needed. Electrocardiogram, heart rate, pulse oximetry and temperature were monitored throughout the surgery.
[0101] To screen for optimal targeted contrast agents, 2-200 nmol of each NIR fluorophore was injected intravenously into CD-1 mice and the animals were sacrificed 1-4 hours after injection (n>3). Target tissues / organs were observed at indicated time points such as 0, 5, 10, 15, 30, 60, 120, 180 and 240 minutes using the FLARE™ imaging system. After intraoperative imaging, the animals were sacrificed and the target tissues and other major organs including heart, lung, liver, spleen, pancreas, kidney, duodenum, intestine and muscle were removed to quantify biodistribution and clearance. For rats, optimized doses (10-1000 nmol) were injected depending on the targeting purpose and the targeting and biodistribution were observed 4 hours after injection (n>3). For large animal studies, the appropriate dose was calculated based on previous dose-dependent studies in small animal studies. To confirm pharmacokinetics in large animals, 0.5-10 μmol of NIR fluorescent protein was injected via the external jugular vein (n>3), and the target tissue and surrounding organs were then imaged at the indicated time points (0, 1, 5, 10, 15, 30, 60, 90, 120, 180, and 240 min).
[0102] Example 3 Comparative Example To demonstrate the superior efficacy of ICB as a contrast agent, ICB was compared with known contrast agents, indocyanine green (ICG) and SLN-700.
[0103] [ka]
[0104] Experimental conditions: ICG: 500 μM reconstituted in water SLN700: 500 μM reconstituted in 50% ethanol / 50% water CUR-438: reconstituted in D5W at 500 μM It was.
[0105] All plantar and intravenous injections were 10 μL each of these concentrations of 500 μM for a total of 5 nmol per injection.
[0106] CD-1 mice were injected with 5 nmol of ICB, indocyanine green, and SLN-700 into the plantar surface of the foot and sacrificed immediately after injection (n>3). The sentinel lymph nodes were observed with a near-infrared (NIR) imaging system.
[0107] The target tissue was exposed and the SLNs were imaged for NIR fluorescence using dual channels [channel 1 (700 nm) and channel 2 (800 nm)] of the NIR imaging system.
[0108] Figure 1 shows a comparison between ICB and indocyanine green. Figure 2 shows a comparison between SLN700 and indocyanine green. Figure 3 shows a comparison between SLN700 and ICB.
[0109] In particular, 15 minutes after injection, a first stage / second stage signal to background ratio of 3.0±0.65 was observed for indocyanine green, 8.1±4.0 for SLN700, and 5.4±1.6 for SLN700 and ICB, respectively. In addition, ICB demonstrates significantly less leakage than ICG or SLN700, as observed by the flow-through fractions of these components. In the ICB view, the sentinel lymph node is clearly identified with little to no significant flow-through fraction. In addition, compared to SLN700, the visualization of ICB is brighter, allowing for easier identification during testing.
[0110] Visible hepatic (liver) clearance of ICB was also observed by imaging, which was significantly more pronounced than SLN700.
[0111] The same procedure using intradermal tail injections was used to visualize lymphatic flow until 15 minutes after injection, when the animals were sacrificed. This procedure was performed by visualization at 700 nm for ICB and SLN700, and 800 nm for ICG. The data are shown in FIG. 4.
[0112] Arrows with squares indicate second tier (axillary) lymph nodes. Arrows with circles indicate first tier nodes. As can be seen in Figure 4, ICG demonstrates significant LN skip compared to ICB or SLN700.
[0113] To demonstrate the biodistribution benefit of ICB, the same procedure was used using intravenous injection. After 4 hours, the animals were sacrificed and the target tissues and other major organs, including heart, lung, liver, spleen, pancreas, kidney, duodenum, intestine and muscle, were removed to quantify biodistribution and clearance. Analysis of the biodistribution of all three dyes 4 hours after iv injection. The data are shown in Figure 5A, Figure 5B and Figure 5C.
[0114] Both ICG and ICB show enhanced signals in the colon, but to a lesser extent in the stomach, suggesting excretion of both dyes by bile. A very small signal was observed in the kidneys with ICB. In contrast, no direct evidence of bile excretion to the colon was observed with SLN700, but both liver and kidney signals were enhanced. Spleen and lung signals were also high with SLN700. This may be related to the high perfusion of both organs. It is evident from this data that ICB, compared with ICG or SLN700, can be completely cleared by the liver, allowing for easier administration and tolerance, and also increasing the effectiveness of sentinel lymph node mapping.
[0115] Example 4 large animal research For large animal studies, appropriate doses were calculated based on previous dose-response studies in animal studies. To confirm pharmacokinetics in large animals, 0.5-10 μmol of NIR fluorescent was injected via the external jugular vein (n>3). Target tissues and surrounding organs were then imaged at the indicated time points (0, 1, 5, 10, 15, 30, 60, 90, 120, 180, and 240 min).
[0116] SLN: 35 kg female pigs with chemically induced tumors are injected intratumorally with 5 nmol indocyanine green dissolved in saline or D5W at time zero. After waiting 5 minutes, the target tissue is exposed and the SLN is imaged for NIR fluorescence using channel 1 (700 nm) or channel 2 (800 nm) of the FLARE imaging system, respectively.
[0117] SLN: 35 kg female pigs with chemically induced tumors are injected intratumorally with 5 nmol indocyanine blue dissolved in saline or D5W at time zero. After waiting 5 minutes, the target tissue is exposed and the SLN is imaged for NIR fluorescence using channel 1 (700 nm) or channel 2 (800 nm) of the FLARE imaging system, respectively.
[0118] SLN: A 35 kg female pig was injected subcutaneously into the intestine at time zero with 5 nmol of compound SML700 (700 nm) dissolved in saline or D5W. After waiting 5 minutes, the target tissue was exposed and the SLN was imaged for NIR fluorescence using channel 1 (700 nm) of the FLARE imaging system. As shown in Figure 6, the SLN is enhanced with high contrast using this compound.
[0119] Example 5 Hydrophobicity measurement The hydrophobicity of ICB, ICG and MHI86 is determined by measuring the octanol-water partition coefficient (log P) of the drug. Negative log P values are characteristic of high water solubility. Such measurements may be performed by the method described in Cumminh, H. and Rucker, C., "Octanol-Water Partition Coefficient Measurement by a Simple 1H NMR Method", ACS Omega, 2017, 2(9), 6244-6249.
[0120] Example 6 Measurement of solubility Indocyanine green has a fairly low water solubility of 2.5 mg / mL. To achieve this solubility, iodide is added to a concentration of 1-5%.
[0121] SLN700 exhibits low solubility in pure water environments such as deionized water and PBS. For R&D purposes, the highest observable solubility is 66 mg / mL in DMSO. However, the contrast agent is soluble in mixtures of water and ethanol. Solubility of SLN700 in water:ethanol formulations was completed by mixing excess contrast agent with premixed solvent. After extensive mixing, the solution was filtered using a 0.45 μm spin filter. A known volume of solvent was then removed by evaporation and solubility was determined by measuring the remaining solids in a premeasured evaporation flask. The results are shown below.
[0122] [Table 1]
[0123] In contrast to the above, indocyanine blue was tested in both water and D5W and found to have a solubility of at least 10 mg / mL in both cases.
[0124] As can be seen from the data above, ICB provides significantly superior results in terms of solubility, allowing for significantly easier and safer formulation and administration of the dye to subjects compared to ICG or SLN700.
[0125] Incorporation by Reference The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein by reference in their entirety.
[0126] Equivalent While the present disclosure has been described with reference to certain embodiments and examples, those skilled in the art having the benefit of this disclosure will appreciate that other embodiments may be devised that do not depart from the scope and spirit of the present disclosure.
[0127] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein which equivalents are intended to be encompassed by the following claims.
[0128] It is understood that the detailed examples and embodiments described herein are given by way of example for illustrative purposes only and are not to be considered as limiting the present disclosure in any way. In view of this, various modifications or changes will be suggested to those skilled in the art and are considered to be within the spirit and scope of this application and the scope of the appended claims. For example, the relative amounts of ingredients may be changed to optimize the desired product, additional ingredients may be added, and / or similar ingredients may be substituted for one or more of the ingredients described.
[0129] Further advantageous features and functions associated with the disclosed systems, methods, and processes will be apparent from the appended claims. Moreover, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein.
Claims
1. (a) administering an imaging composition to an organism that includes a lymph node, the imaging composition comprising an imaging agent, and administering the imaging composition comprises contacting a sentinel lymph node with the imaging agent; wherein the imaging agent is 【Chemistry 1】 or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the tissue, lumen or cells of the sentinel lymph node with a wavelength absorbed by the imaging agent; (c) detecting a signal from the imaging agent, thereby imaging the lymph node. Methods for imaging sentinel lymph nodes.
2. The method of claim 1 , wherein the organism is a human.
3. 2. The method of claim 1, wherein the imaging agent has an absorbance peak at about 600 nm to 850 nm.
4. The method of claim 1, wherein the lymph node is imaged in vivo.
5. 2. The method of claim 1, wherein the administering step is carried out by intratumoral administration, subdermal administration, subcutaneous administration, parenchymal administration, or a combination thereof.
6. (a) administering an imaging composition to an organism that contains a sentinel lymph node, said imaging composition comprising an imaging agent, and said administering step comprising contacting said sentinel lymph node with said imaging agent; wherein the imaging agent is 【Chemistry 2】 or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the sentinel lymph node with a wavelength absorbed by the imaging agent; (c) detecting a signal from the imaging agent, thereby mapping the sentinel lymph node. A method for mapping sentinel lymph nodes in an organism.
7. The method of claim 6, wherein the organism is a human.
8. 7. The method of claim 6, wherein the imaging agent has an absorbance peak at about 600 nm to 850 nm.
9. 7. The method of claim 6, wherein the administering step is carried out by intratumoral administration, subdermal administration, subcutaneous administration, parenchymal administration, or a combination thereof.
10. (a) administering to an organism an imaging composition, said imaging composition comprising an imaging agent, and said administering step comprising contacting a sentinel lymph node of said organism with the imaging agent; The imaging agent is 【Chemistry 3】 or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the sentinel lymph node with a wavelength absorbed by the imaging agent; (c) detecting a signal from the imaging agent and identifying the sentinel lymph node; (d) analyzing the identified sentinel lymph nodes using frozen section or conventional histopathology; (e) determining whether the sentinel lymph node removed in the biopsy contains malignant cancer cells; A method for identifying malignant cancer cells in an organism.
11. 11. The method of claim 10, wherein the administering step is carried out by intratumoral administration, subdermal administration, subcutaneous administration, parenchymal administration, or a combination thereof.
12. (a) administering to an organism an imaging composition, said imaging composition comprising an imaging agent, and said administering step comprising contacting a blood vessel, a blood vessel of a lymph node, and / or a coronary cavity of said organism with said imaging agent; wherein the imaging agent is 【Chemistry 4】 or a salt, solvate, hydrate, polymorph or prodrug thereof; (b) irradiating the blood vessel, lymph node and / or coronary cavity with a wavelength absorbed by the imaging agent; (c) detecting a signal from the imaging agent and identifying the blood vessel, lymph node, and / or coronary cavity. A method for performing angiography in an organism.
13. 13. The method of claim 12, wherein the administering step is carried out by intravenous administration.
Citation Information
Patent Citations
Imaging device and manufacturing method of imaging device
JP2013156347A
Particle, contrast medium for optoacoustic imaging having the particle, and contrast medium for sentinel lymph node
JP2013224289A
Near-infrared fluorescence contrast bioimaging agent and method of use thereof
JP2017503004A
Sentinel lymph node imaging agent
JP2021147316A
A cyanine-based probe\tag-peptide pair for fluorescence protein imaging and fluorescence protein imaging methods
EP2152810A1
